Search Results
Your search for ,iII matches 9602 pages
Showing 9001 - 9050UK Trial of PET-Directed Therapy Suggests That No Radiotherapy May Be an Option in PET-Negative Early-Stage Hodgkin Lymphoma
In a UK phase III RAPID trial reported in The New England Journal of Medicine, Radford et al compared no further treatment vs involved-field radiotherapy in patients with early-stage Hodgkin lymphoma who had negative positron emission tomography (PET) findings after 3 cycles of doxorubicin,...
Anti–PD-1 Antibody Pembrolizumab Improves Progression-Free and Overall Survival vs Ipilimumab in Advanced Melanoma
In the phase III KEYNOTE-006 trial reported in The New England Journal of Medicine, Robert et al found that the anti–PD-1 antibody pembrolizumab (Keytruda) increased progression-free and overall survival compared with ipilimumab in patients with advanced melanoma. Study Details In this...
Collaboration Between Surgeons and Medical Oncologists Improves Outcomes for Patients With Stage III Colon Cancer
Collaboration between surgeons and medical oncologists specialists “is associated with lower mortality without increased cost among patients with stage III colon cancer,” according to a study by Hussain et al in the Journal of Oncology Practice. An increase from one to five in the...
Addition of Nivolumab to Ipilimumab Improves Response Rate and Progression-Free Survival in Previously Untreated Advanced Melanoma
In a phase II study reported in The New England Journal of Medicine, Postow et al found that dual checkpoint inhibitor therapy with the anti–CTLA-4 antibody ipilimumab (Yervoy) and the anti–PD-1 monoclonal antibody nivolumab (Opdivo) produced greater response rates and prolonged...
Phase II Study Shows Addition of Pazopanib to Paclitaxel Improves Progression-Free Survival in Platinum-Resistant/Refractory Advanced Ovarian Cancer
In an Italian randomized phase II trial reported in The Lancet Oncology, Pignata et al found that the addition of the antiangiogenic multikinase inhibitor pazopanib (Votrient) to weekly paclitaxel significantly improved progression-free survival in patients with platinum-resistant/refractory...
Genomic Analyses Point to the Potential of Personalized Care for Liver Cancer Patients
A new study presented at The International Liver Congress 2015 in Vienna showed that using genomic analyses to understand how and when carcinogenic mutations occur in patients with hepatocellular carcinoma may make it possible to identify specific molecular profiles linked to tumor aggressiveness...
Addition of Ofatumumab to Chlorambucil Increases Progression-Free Survival in Previously Untreated CLL Patients Who Are Not Candidates for Fludarabine
In the phase III COMPLEMENT 1 trial reported in The Lancet, Hillmen et al found that the addition of the anti-CD20 antibody ofatumumab (Arzerra) to chlorambucil (Leukeran) increased progression-free survival among patients with chronic lymphocytic leukemia (CLL) who were not considered candidates...
FDA Approves Ramucirumab for Metastatic Colorectal Cancer
The U.S. Food and Drug Administration today approved ramucirumab (Cyramza) for use in combination with FOLFIRI (leucovorin, fluorouracil, irinotecan) for the treatment of patients with metastatic colorectal cancer whose disease has progressed on a first-line bevacizumab (Avastin)-, oxaliplatin-,...
Addition of Ramucirumab to Second-Line FOLFIRI Improves Overall Survival in Metastatic Colorectal Cancer
In the phase III RAISE trial reported in The Lancet Oncology, Tabernero et al found that the addition of the antiangiogenic anti-VEGFR2 antibody ramucirumab (Cyramza) to second-line FOLFIRI (leucovorin, fluorouracil, irinotecan) improved overall survival in patients with metastatic colorectal...
Afatinib Improves Progression-Free Survival vs Methotrexate in Platinum-Treated Recurrent or Metastatic Head and Neck Cancer
In the phase III LUX-Head & Neck 1 trial reported in The Lancet Oncology, Machiels et al found that afatinib (Gilotrif) improved progression-free survival vs methotrexate in patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing after first-line platinum...
Pretreatment PET Metabolic Tumor Volume Is Associated With Outcome in Stage III NSCLC
In a study reported in the Journal of the National Cancer Institute, Ohri et al found that higher pretreatment metabolic tumor volume on 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) was associated with poorer overall survival and an increased risk of locoregional failure in...
AACR 2015: Pembrolizumab Is Better Than Ipilimumab for Advanced Melanoma in Phase III Trial
In the first randomized trial to compare two U.S. Food and Drug Administration–approved immune checkpoint inhibitors as first-line therapy for patients with advanced melanoma, pembrolizumab (Keytruda) yielded significantly better treatment outcomes than ipilimumab (Yervoy) for all endpoints...
Do Survival Gains Match More Intense Treatment in Younger Patients With Colon Cancer?
In a study reported in JAMA Surgery, Kneuertz et al found that the more frequent stage-specific use of adjuvant chemotherapy in younger patients with colon cancer did not appear to produce commensurate benefit in survival compared with outcomes in older patients. Study Details The study was a...
Evidence Grows That Melanoma Drugs May Benefit Some Lung Cancer Patients
A subset of lung cancer patients can derive important clinical benefits from drugs that are more commonly used to treat melanoma, the authors of a new academic clinical trial in Europe have reported at the European Lung Cancer Conference (ELCC) in Geneva (Abstract 21PD_PR). Oliver Gautschi, MD, a...
Circulating Tumor Cell Count and LDH Level as Patient-Level Surrogate for Survival in Metastatic Castration-Resistant Prostate Cancer
In an analysis reported in the Journal of Clinical Oncology, Scher et al found that circulating tumor cell count and LDH level served as an individual-level surrogate for survival among patients with metastatic castration-resistant prostate cancer receiving abiraterone acetate (Zytiga) plus...
No Survival Benefit of Vorinostat in Progressive Advanced Malignant Pleural Mesothelioma
In the phase III VANTAGE-014 study reported in The Lancet Oncology, Krug et al found that treatment with the histone deacetylase inhibitor vorinostat (Zolinza) did not improve overall survival vs placebo in patients with malignant pleural mesothelioma who had progressed on previous chemotherapy....
Worse Outcomes With Lapatinib vs Trastuzumab Plus Taxane in Advanced HER2-Positive Breast Cancer
In the phase III National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) MA.31 trial, first-line treatment with lapatinib (Tykerb) vs trastuzumab (Herceptin) combined with a taxane was associated with poorer progression-free survival and greater toxicity in patients with advanced...
Adjuvant Ipilimumab Increases Recurrence-Free Survival vs Placebo After Complete Resection of High-Risk Stage III Melanoma
In the phase III EORTC 18071 trial reported in The Lancet Oncology, Eggermont et al found that adjuvant ipilimumab (Yervoy) significantly improved recurrence-free survival vs placebo in patients with completely resected stage III melanoma at high risk of disease recurrence. Ipilimumab was...
Five-Year Analysis Indicates Potential for Long‑Term Survival With Ipilimumab Plus Dacarbazine in Advanced Melanoma
In an analysis reported in the Journal of Clinical Oncology, Maio et al found a 5-year survival rate of 18% among treatment-naive patients receiving ipilimumab (Yervoy) plus dacarbazine in a phase III trial. The findings support other data indicating long-term survival in some patients receiving...
Erythropoietin Plus Radiation Therapy Does Not Improve Local-Regional Control in Anemic Patients With Head and Neck Cancer
Long-term analysis of Radiation Therapy Oncology Group (RTOG) 9903 demonstrates that the addition of erythropoietin did not improve local-regional control for anemic patients with head and neck squamous cell carcinoma who receive radiation therapy or chemoradiation, according to a study published...
Improved Progression-Free Survival With Brentuximab Vedotin Consolidation After Transplantation in Hodgkin Lymphoma
In the phase III AETHERA trial reported in The Lancet, Moskowitz et al found that brentuximab vedotin (Adcetris) consolidation therapy after autologous stem cell transplantation prolonged progression-free survival by 18 months vs placebo in patients with Hodgkin lymphoma at risk for relapse or...
Nocturnal Cortisol Levels May Provide a Noninvasive Biomarker of Ovarian Cancer Severity
Elevated nocturnal cortisol levels prior to surgery in patients with ovarian cancer were associated with shorter survival time, according to a study by Schrepf et al in Psychoneuroendocrinology. Thus, night-time cortisol levels may prove to be a noninvasive biomarker of ovarian cancer disease...
Nivolumab Increases Response Rate vs Chemotherapy in Advanced Melanoma With Progression After Anti–CTLA-4 Treatment
In the phase III CheckMate 037 trial reported in The Lancet Oncology, Weber et al found that treatment with the PD-1 inhibitor nivolumab (Opdivo) resulted in a significantly greater response rate vs chemotherapy as second- or later-line treatment in patients with advanced melanoma progressing after ...
No Differences in Patient-Reported Outcomes or Resource Use With Early vs Delayed Initiation of Palliative Care Intervention
In the ENABLE III study reported in the Journal of Clinical Oncology, Bakitas et al found that early vs delayed initiation of a palliative care intervention did not result in improved patient-reported outcomes or resource use. Early initiation was associated with better 1-year survival. Study...
Reduced Family Caregiver Depression With Early vs Delayed Palliative Care Intervention for Caregivers
In the ENABLE III study reported in the Journal of Clinical Oncology, Dionne-Odom et al found that early vs delayed use of a palliative care intervention for family caregivers of patients with advanced cancer reduced caregiver depression scores and caregiver stress burden. No differences in...
Intraperitoneal Chemotherapy Associated With Long-Term Survival Advantage Over Intravenous Chemotherapy in Advanced Ovarian Cancer
In an analysis of Gynecologic Oncology Group (GOG) studies reported in the Journal of Clinical Oncology, Tewari et al found that intraperitoneal chemotherapy was associated with a survival advantage compared with intravenous chemotherapy in women with advanced ovarian cancer. Study Details The...
Experimental Immunotherapy Delays Recurrence for Stage III and IV Ovarian Cancers
According to a phase II study presented at the Society of Gynecologic Oncology Annual Meeting on Women’s Cancer, an experimental immunotherapy is in the works that can target an individual woman’s ovarian tumor and extend the time period between initial treatment and the cancer’s...
Addition of Bevacizumab to Chemotherapy Extends Survival in Women With Platinum-Sensitive Recurrent Ovarian Cancer
In a phase III study of women with ovarian cancer, researchers found that the addition of bevacizumab (Avastin) to standard chemotherapy extended median overall survival by 5 months compared to standard chemotherapy alone. The bevacizumab combination was also associated with a significant...
Italian Trial Shows Benefit of Dose-Dense Adjuvant Therapy With Sequential Epirubicin-Cyclophosphamide-Paclitaxel in Early Node-Positive Breast Cancer
In an Italian 2×2 phase III trial reported in The Lancet, Del Mastro et al found that dose-dense adjuvant therapy with sequential epirubicin, cyclophosphamide, and paclitaxel (EC-P) with or without fluorouracil (5-FU) increased disease-free survival vs standard-interval therapy in early-stage ...
Improved Outcome and Greater Use of Adjuvant Chemotherapy With Laparoscopic vs Open Colectomy in Nonmetastatic Colon Cancer
In a National Cancer Data Base analysis reported in the Journal of the National Cancer Institute, Zheng et al found that laparoscopic colectomy was associated with lower 30-day mortality, shorter length of stay, and, in patients with stage III disease, greater use of adjuvant chemotherapy vs open...
FDA Grants Priority Review to Carfilzomib Supplemental New Drug Application for Relapsed Multiple Myeloma
The U.S. Food and Drug Administration (FDA) has accepted Amgen’s supplemental New Drug Application (sNDA) for carfilzomib (Kyprolis) injection for the treatment of patients with relapsed multiple myeloma who have received at least one prior therapy. The sNDA is designed to support the...
No Survival Benefit of IGF-1R/Insulin Receptor Inhibitor Linsitinib in Advanced Adrenocortical Carcinoma
In a phase III trial reported in The Lancet Oncology, Fassnacht et al found that linsitinib, an insulin-like growth factor 1 receptor (IGF-1R) and insulin receptor inhibitor, did not improve overall survival vs placebo in patients with previously treated locally advanced or metastatic...
Women With Diabetes More Likely to be Diagnosed With Advanced-Stage Breast Cancer
Diabetes is associated with more advanced stage breast cancer, according to a new study by the Institute for Clinical Evaluative Sciences (ICES) and Women's College Hospital. The findings, published by Lipscombe et al in Breast Cancer Research and Treatment, confirm a strong link between diabetes...
Elevated C-Reactive Protein Associated With Poorer Outcome in Melanoma
In a study reported in the Journal of Clinical Oncology, Fang et al found that an elevated C-reactive protein level was associated with poorer overall and melanoma-specific survival in patients with melanoma and that sequential increases in C-reactive protein were associated with an increased risk...
No Improvement in Complete Remission Rate With Cytarabine Plus Amonafide L-Malate vs Daunorubicin in Secondary AML
In a phase III trial reported in the Journal of Clinical Oncology, Stone et al found that the combination of cytarabine and amonafide L-malate, a DNA intercalator and non–ATP-dependent topoisomerase II inhibitor, did not improve complete remission rate compared with cytarabine plus...
Addition of Lenalidomide to Docetaxel-Prednisone Worsens Survival in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
In the phase III MAINSAIL trial reported in The Lancet Oncology, Petrylak et al found that the addition of lenalidomide (Revlimid) to docetaxel-prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer was associated with significantly worse overall survival. The...
Nivolumab Shows Activity in Advanced, Refractory Squamous NSCLC
In the phase II CheckMate 063 study reported in The Lancet Oncology, Rizvi et al found that the PD-1 inhibitor nivolumab (Opdivo) produced durable responses in some patients with advanced, refractory squamous non–small cell lung cancer (NSCLC) who had received at least two prior treatments....
Addition of Aprepitant to Ondansetron Effective in Preventing Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients
In a phase III trial reported in The Lancet Oncology, Kang et al found that adding aprepitant to ondansetron with or without dexamethasone was effective in preventing chemotherapy-induced nausea and vomiting in pediatric patients receiving moderately or highly emetogenic chemotherapy. Study...
Findings in Pooled Analysis of Long-Term Survival With Ipilimumab in Advanced Melanoma
In a pooled analysis reported in the Journal of Clinical Oncology, Schadendorf et al found 3-year overall survival rates of 26% and 20% in treatment-naive and previously treated patients receiving ipilimumab (Yervoy)-based treatment for unresectable or metastatic melanoma. A survival curve plateau...
Goserelin Provides Ovarian Protection During Adjuvant Chemotherapy for Breast Cancer
In the phase III POEMS/S0230 trial reported in The New England Journal of Medicine, Moore et al found that treatment with the gonadotropin-releasing hormone agonist goserelin (Zoladex) reduced risk of ovarian failure during chemotherapy for breast cancer in premenopausal women. Study Details In...
Substitution of Bortezomib for Vincristine in R‑CHOP Improves Progression-Free Survival in First-Line Therapy for Mantle Cell Lymphoma
In a phase III trial reported in The New England Journal of Medicine, Robak et al found that VR-CAP, a regimen replacing vincristine with bortezomib (Velcade) in R-CHOP (rituximab [Rituxan], cyclophosphamide, doxorubicin, vincristine, and prednisone), significantly improved progression-free...
Concurrent Chemoradiation Therapy at High-Volume Facilities Improves Survival for NSCLC
Patients treated with definitive concurrent chemotherapy and radiation therapy for stage III non–small cell lung cancer (NSCLC) have longer overall survival when treated by highly experienced facilities, whether or not they are academic or community cancer centers. Researchers from the Yale...
Left-Sided Primary Tumor Location More Common and Associated With Better Survival in Metastatic Colorectal Cancer
In a study reported in the Journal of the National Cancer Institute, Loupakis et al found that most treatment-naive patients with metastatic colorectal cancer had left-sided primary tumor location and that left-sided tumor location was associated with improved overall survival. Study Details The...
Clinical Trial Suggests Temozolomide-Based Chemoradiation Is Best for Low-Grade Brain Tumors
New clinical trial findings provide further evidence that combining chemotherapy with radiation therapy is the best treatment for people with a low-grade form of brain cancer. The findings come from a phase II study co-led by a researcher at Ohio State University Comprehensive Cancer...
No Benefit of Adding Bevacizumab to First-Line Gemcitabine-Docetaxel in Metastatic Uterine Leiomyosarcoma
In a phase III NRG Oncology/Gynecologic Oncology Group (GOG) trial reported in the Journal of Clinical Oncology, Hensley et al found no benefit of adding bevacizumab (Avastin) to first-line gemcitabine-docetaxel in patients with metastatic uterine leiomyosarcoma. Study Details In this...
Greater Guideline Adherence, Better Survival, Absence of Racial Survival Disparity Among Colorectal Cancer Patients in Integrated Health-Care System
In a retrospective analysis reported in the Journal of Clinical Oncology, Rhoads et al found that treatment of colorectal cancer patients in an integrated health-care system was associated with greater compliance with National Comprehensive Cancer Network (NCCN) guidelines, better survival, and no...
Addition of Orteronel to Prednisone in Metastatic Castration-Resistant Prostate Cancer Does Not Meet Overall Survival Endpoint in Phase III Trial
In a phase III trial (ELM-PC 5) reported in the Journal of Clinical Oncology, Fizazi et al found that the addition of the 17,20-lyase inhibitor orteronel to prednisone in patients with metastatic castration-resistant prostate cancer progressing after docetaxel therapy resulted in an overall...
Complex Surgery Does Not Independently Predict Outcome in Advanced Ovarian Cancer
In an analysis in the Gynecologic Oncology Group (GOG 182) trial population reported in the Journal of Clinical Oncology, Horowitz et al found that more complex surgery was not an independent predictor of progression-free or overall survival among patients with advanced epithelial ovarian or...
Acceptable Cardiac Safety of Ado-Trastuzumab Emtansine After Anthracycline-Based Chemotherapy in Early-Stage HER2-Positive Breast Cancer
In a study reported in the Journal of Clinical Oncology, Krop et al found that ado-trastuzumab emtansine (Kadcyla) had an acceptable cardiac safety profile when used after anthracycline-based (neo)adjuvant therapy in women with early-stage HER2-positive breast cancer. Study Details In the study,...
No Improvement in Overall Survival With Addition of Anti-EGFR Antibody Necitumumab to First-Line Pemetrexed-Cisplatin in Metastatic Nonsquamous NSCLC
In the phase III INSPIRE trial reported in The Lancet Oncology, Paz-Ares et al found that the addition of the anti-EGFR IgG1 monoclonal antibody necitumumab to first-line pemetrexed (Alimta)-cisplatin did not improve overall survival in patients with previously untreated stage IV nonsquamous...
